Study of LB1410 and lenvatinib with or without LB4330 for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs for people with advanced cervical cancer that has come back or spread, and who have already tried standard treatments. It aims to see if adding these experimental drugs to lenvatinib is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cervical cancer is a specific type (squamous cell, adenosquamous, or HPV-related adenocarcinoma) that has come back or spread.
- You have tried at least one standard treatment but it stopped working or caused too many side effects.
- You have had no more than three prior treatments for advanced cancer, and only one of those was an immunotherapy like Keytruda or Opdivo.
- You are 18 or older, feel well enough to do daily activities (ECOG 0 or 1), and have a life expectancy of at least 12 weeks.
- Your kidneys, liver, and blood counts are working well enough, and your blood pressure is controlled.
- You do not have active or unstable brain metastases, a history of severe bleeding, or an active infection like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.